GTC
MLTX icon

Ghost Tree Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ghost Tree Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-250,000
Closed -$15.1M – 79
2023
Q4 		$15.1M Buy
+250,000
New +$12.9M 4.94% 4

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ghost Tree Capital's MLTX Position: Q3 2024 in Review

Ghost Tree Capital reduced its MoonLake Immunotherapeutics (MLTX) stake by 57% in Q3 2024, selling an estimated $8.04M and leaving 128,411 shares worth $6.47M. The position accounts for 1.96% of the portfolio, ranked #21.

Ghost Tree Capital first reported a position in MLTX in Q4 2020 and has held it in 13 quarters since. The position peaked at $18.8M in Q3 2023. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

  • Ghost Tree Capital held 128,411 shares of MoonLake Immunotherapeutics worth $6.47M as of Q3 2024.
  • Ghost Tree Capital sold 171,589 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $8.04M.
  • MoonLake Immunotherapeutics made up 1.96% of Ghost Tree Capital's portfolio in Q3 2024, its #21 holding.
  • Ghost Tree Capital first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 13 quarters since.
  • Ghost Tree Capital's MoonLake Immunotherapeutics position peaked at $18.8M in Q3 2023.
  • 109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.